Sevindik, ÖmürGemici, AliihsanMutlu, Yaşa GülBalık Aydın, BerrinÇakır, Aslı2020-09-282020-09-282020Sevindik, Ö., Gemici, A., Mutlu, Y. G., Balık Aydın, B. ve Çakır, A. (2020). Rituximab-vemurafenib combination for the treatment of relapsed/Refractory hairy cell leukemia. Clinical Lymphoma, Myeloma & Leukemia içinde (S286-S286. ss.).2152-26502152-2669https://hdl.handle.net/20.500.12511/5870Objective: The management of R/R-HCL is not standardized yet. Patients with HCL universally harbor BRAF mutations, which makes BRAF inhibitors a potential treatment approach. The effi cacy and safety of the BRAF inhibitor Vemurafenib were evaluated both as a single-agent option in two phase 2 trials and also combined with Rituximab in another phase 2 trial. Patients: We have decided to present the fi rst two consecutive patients who achieved a rapid and prolonged response, relapsing after treatment with purine analogues. The fi rst two patients who received a combination of R-V for R/R HCL from the records of our institutional CLPD registry were reported.eninfo:eu-repo/semantics/embargoedAccessHairy Cell LeukemiaHCLCombination TherapyRituximabVemurafenibConference Object20Supplement: 1S286S286Q3